Cargando…
Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study
BACKGROUND: A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was immunologically non-inferior to the HSA-c...
Autores principales: | Faust, Saul N., Le Roy, Maguelone, Pancharoen, Chitsanu, Weber, Miguel Angel Rodriguez, Cathie, Katrina, Behre, Ulrich, Bernatoniene, Jolanta, Snape, Matthew D., Helm, Klaus, Medina Pech, Carlos Eduardo, Henry, Ouzama, Baccarini, Carmen, Povey, Michael, Gillard, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366055/ https://www.ncbi.nlm.nih.gov/pubmed/30732648 http://dx.doi.org/10.1186/s12887-019-1425-7 |
Ejemplares similares
-
hsa_circ_0072389, hsa_circ_0072386, hsa_circ_0008621, hsa_circ_0072387, and hsa_circ_0072391 aggravate glioma via miR-338-5p/IKBIP
por: Liang, Jian, et al.
Publicado: (2021) -
2355. Clinically vs. Serologically Identified Varicella: A Hidden Infection Burden. Lessons of 10-Year Follow-up in Varicella Endemic Countries
por: Gillard, Paul, et al.
Publicado: (2018) -
Comparison of Losartan and Furosemide Interaction with HSA and Their Influence on HSA Antioxidant Potential
por: Rogóż, Wojciech, et al.
Publicado: (2022) -
Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries
por: Gillard, Paul, et al.
Publicado: (2021) -
HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment
por: Shen, Yuzhou, et al.
Publicado: (2018)